Myriad Genetics Inc. (MYGN)

[surf1944]

7:06AM Myriad Genetics to present PROLARIS data at ASCO 2013, continuing its commitment to cancer research says 'clinical data show that prolaris predicts prostate cancer outcome in multiple patient cohorts and in diverse clinical settings' (MYGN) 31.67 : "Clinical data show that PROLARIS predicts prostate cancer outcome in multiple patient cohorts and in diverse clinical settings," said Professor Cuzick. "PROLARIS provides independent information beyond clinicopathologic variables and accurately differentiates aggressive prostate cancer from indolent cancer based on real oncologic outcomes." Key clinical characteristics of PROLARIS include: The PROLARIS Score is the dominant variable at diagnosis in predicting risk of prostate cancer progression, as determined by the gold standard oncologic endpoints such as biochemical recurrence, metastasis and prostate cancer specific mortality.